Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Vaccine ; 36(50): 7632-7640, 2018 11 29.
Artículo en Inglés | MEDLINE | ID: mdl-30392766

RESUMEN

The CD8+ T-cell response is an essential part of the adaptive immunity. Adjuvants are routinely required for priming of T cells against antigens encountered in lymph nodes (LNs) to generate antigen-specific immunity but may concomitantly trigger unexpected inflammatory responses. Sphingosine-1-phosphate (S1P) induces transient desensitization of S1P receptors on LN T cells and temporarily blocks their egress, leading to prolonged intranodal retention that allows effective immunosurveillance and increases the chance of priming. In light of the regulatory role of S1P in T-cell migration, we here develop a strategic approach to the T-cell priming with protein vaccine containing low-dose TLR-based adjuvants (LDAV) to induce antigen-specific CD8+ T cell responses as efficiently as using regular dose adjuvants in vaccine (RDAV). We found that when combined with one low dose of the S1P analog fingolimod administered into the same vaccination site posteriorly at a specific time, LDAV can elicit a primary response that reaches the level of that induced by RDAV with respect to the response magnitude and functionality. Time-course studies indicate that LDAV and fingolimod in combination act to mimic the expansion kinetics of RDAV-primed antigen-specific CD8+ T cells. Further, intranodal accumulation of cDC1 is markedly enhanced in mice receiving the combination vaccination despite the decrease in adjuvant use. Of particular note is the marginal cutaneous inflammation at the injection site, indicating an added benefit of using fingolimod. Therefore, fingolimod as a nonadjuvant agent essentially facilitates antigen-specific T-cell priming with reduced need of adjuvants and minimized adverse reactions.


Asunto(s)
Clorhidrato de Fingolimod/metabolismo , Factores Inmunológicos/metabolismo , Ovalbúmina/inmunología , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Animales , Anticuerpos/sangre , Citocinas/análisis , Ensayo de Inmunoadsorción Enzimática , Clorhidrato de Fingolimod/administración & dosificación , Factores Inmunológicos/administración & dosificación , Inyecciones Subcutáneas , Ratones Endogámicos C57BL , Ovalbúmina/administración & dosificación , Vacunas de Subunidad/administración & dosificación , Vacunas de Subunidad/inmunología
2.
Yao Xue Xue Bao ; 51(6): 873-8, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-29878740

RESUMEN

Lipid second messenger sphingosine-1-phosphate (S1P) can activate sphingosine-1-phosphate receptors (S1PRs) and participate in many biological processes, such as central nervous system homeostasis, cytokine production and T cell migration. S1PR1 is the main S1PR expressed on T cell surface. The interaction between S1P and S1PR1 plays a core role in T cell migration, which is important for T cell maturation, homing and activation. The central function of S1P/S1PR1 in T cell migration made it a popular drug target in treatment research of immune diseases. This review summarizes the current knowledge of the mechanism of S1P/S1PR1 mediating T cell migration and the research progress of S1P/S1PR1 as drug target.


Asunto(s)
Movimiento Celular , Lisofosfolípidos/metabolismo , Receptores de Lisoesfingolípidos/metabolismo , Esfingosina/análogos & derivados , Linfocitos T/citología , Animales , Sistema Nervioso Central , Citocinas/metabolismo , Homeostasis , Humanos , Esfingosina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...